• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拷贝数变异:一种用于甲状腺乳头状癌的新型分子标志物。

Copy number variations: A novel molecular marker for papillary thyroid cancer.

作者信息

Lai Xingjian, Gao Luying, Zhou Gaoying, Xu Xiequn, Wang Jinhui

机构信息

Department of Ultrasound, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Beijing Longer Gene Technology Co., Ltd., Beijing, China.

出版信息

Heliyon. 2022 Oct 17;8(10):e11107. doi: 10.1016/j.heliyon.2022.e11107. eCollection 2022 Oct.

DOI:10.1016/j.heliyon.2022.e11107
PMID:36299525
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9589167/
Abstract

BACKGROUND

We aimed to screen tumor-associated functional genes on a large scale through copy number variation (CNV) analysis of papillary thyroid cancer (PTC).

METHODS

We analyzed 74 tissue samples from 41 patients with thyroid nodules. The samples were subjected to whole-genome resequencing and then analyzed by the 'WISECONDOR' method. Potential chromosome CNV regions were identified between the different sample groups.

RESULTS

Of the 74 samples from 41 patients, 28 were PTC tissue samples, 29 were para-carcinoma tissue samples, 13 were benign tumor tissue samples and 4 were para-benign tumor tissue samples. According to our findings, PTC can be identified by CNVs at the corresponding positions on chromosomes 5, 7, 8, 10, and 17. For carcinoma tissue, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy and area under the curve (AUC) of the test method were 100%, 66.7%, 87.5%, 100.0%, 90.0% and 0.83 (95% confidence interval [CI], 0.67-1.00) and for para-carcinoma tissue, these values were 96.6%, 75.0%, 96.6%, 75.0%, 93.9% and 0.86 (95% CI, 0.60-1.00).

CONCLUSION

CNV analysis assays involving high-volume sequencing analysis can increase the identification of PTC, potentially avoiding errors caused by position deflection in sampling.

摘要

背景

我们旨在通过对甲状腺乳头状癌(PTC)的拷贝数变异(CNV)分析大规模筛选肿瘤相关功能基因。

方法

我们分析了41例甲状腺结节患者的74份组织样本。对样本进行全基因组重测序,然后采用“WISECONDOR”方法进行分析。在不同样本组之间鉴定潜在的染色体CNV区域。

结果

在41例患者的74份样本中,28份为PTC组织样本,29份为癌旁组织样本,13份为良性肿瘤组织样本,4份为良性肿瘤旁组织样本。根据我们的研究结果,PTC可通过染色体5、7、8、10和17上相应位置的CNV来识别。对于癌组织,该检测方法的灵敏度、特异度、阳性预测值(PPV)、阴性预测值(NPV)、准确度和曲线下面积(AUC)分别为100%、66.7%、87.5%、100.0%、90.0%和0.83(95%置信区间[CI],0.67 - 1.00);对于癌旁组织,这些值分别为96.6%、75.0%、96.6%、75.0%、93.9%和0.86(95%CI,0.60 - 1.00)。

结论

涉及高通量测序分析的CNV分析检测可提高PTC的识别率,可能避免采样中位置偏移导致的误差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4de0/9589167/703c2b457423/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4de0/9589167/f44ab8187232/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4de0/9589167/55ca3ab2f212/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4de0/9589167/0b47dbda4af1/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4de0/9589167/703c2b457423/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4de0/9589167/f44ab8187232/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4de0/9589167/55ca3ab2f212/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4de0/9589167/0b47dbda4af1/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4de0/9589167/703c2b457423/gr4.jpg

相似文献

1
Copy number variations: A novel molecular marker for papillary thyroid cancer.拷贝数变异:一种用于甲状腺乳头状癌的新型分子标志物。
Heliyon. 2022 Oct 17;8(10):e11107. doi: 10.1016/j.heliyon.2022.e11107. eCollection 2022 Oct.
2
Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation.通过微阵列荟萃分析鉴定 SERPINA1 作为甲状腺乳头状癌的单一标志物,并在独立验证中定量其鉴别能力。
BMC Med Genomics. 2011 Apr 6;4:30. doi: 10.1186/1755-8794-4-30.
3
Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".BRAF突变检测在细针穿刺活检样本中诊断为“疑似甲状腺乳头状癌”时的应用价值
Head Neck. 2015 Dec;37(12):1788-93. doi: 10.1002/hed.23829. Epub 2014 Sep 25.
4
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.细针抽吸细胞学检查甲状腺乳头状癌时 BRAF V600E 基因突变呈假阴性。
World J Surg Oncol. 2017 Nov 13;15(1):202. doi: 10.1186/s12957-017-1266-5.
5
T2* mapping at 3.0T MRI for differentiation of papillary thyroid carcinoma from benign thyroid nodules.3.0T磁共振成像的T2* 映射用于鉴别甲状腺乳头状癌与甲状腺良性结节。
J Magn Reson Imaging. 2016 Apr;43(4):956-61. doi: 10.1002/jmri.25041. Epub 2015 Sep 21.
6
Clinical diagnostic value of American College of Radiology thyroid imaging report and data system in different kinds of thyroid nodules.美国放射学院甲状腺影像报告和数据系统在不同类型甲状腺结节中的临床诊断价值。
BMC Endocr Disord. 2022 May 31;22(1):145. doi: 10.1186/s12902-022-01053-z.
7
Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.综合 microRNA 表达谱分析鉴定滤泡型甲状腺癌的新型标志物。
Thyroid. 2013 Nov;23(11):1383-9. doi: 10.1089/thy.2012.0632. Epub 2013 Sep 19.
8
Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.利用网络分析鉴定甲状腺乳头状癌免疫浸润和预后中的铁死亡基因
BMC Genomics. 2021 Jul 27;22(1):576. doi: 10.1186/s12864-021-07895-6.
9
The diagnostic application of RNA sequencing in patients with thyroid cancer: an analysis of 851 variants and 133 fusions in 524 genes.RNA测序在甲状腺癌患者中的诊断应用:对524个基因中的851个变异和133个融合的分析
BMC Bioinformatics. 2016 Jan 11;17 Suppl 1(Suppl 1):6. doi: 10.1186/s12859-015-0849-9.
10
A panel of four genes accurately differentiates benign from malignant thyroid nodules.由四个基因组成的一组能够准确区分甲状腺良性结节和恶性结节。
J Exp Clin Cancer Res. 2016 Oct 28;35(1):169. doi: 10.1186/s13046-016-0447-3.

本文引用的文献

1
Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT process in bladder cancer.NDRG1 的上调通过影响膀胱癌中的 EMT 过程预测不良预后并促进疾病进展。
Sci Rep. 2019 Mar 26;9(1):5166. doi: 10.1038/s41598-019-41660-w.
2
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.145例甲状腺癌连续队列中的TERT启动子突变及其与BRAF和RAS突变的相关性
Oncol Lett. 2018 Mar;15(3):2763-2770. doi: 10.3892/ol.2017.7675. Epub 2017 Dec 21.
3
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
个体前列腺癌病灶内的基因组异质性影响靶向治疗的预测性生物标志物。
Eur Urol Focus. 2019 May;5(3):416-424. doi: 10.1016/j.euf.2018.01.006. Epub 2018 Feb 15.
4
Molecular testing of BRAF, RAS and TERT on thyroid FNAs with indeterminate cytology improves diagnostic accuracy.对甲状腺细针穿刺活检(FNA)结果为不明确的样本进行BRAF、RAS和端粒酶逆转录酶(TERT)的分子检测可提高诊断准确性。
Cytopathology. 2017 Dec;28(6):482-487. doi: 10.1111/cyt.12493. Epub 2017 Nov 2.
5
Clinical and genetic characterization of hereditary breast cancer in a Chinese population.中国人群遗传性乳腺癌的临床与遗传学特征
Hered Cancer Clin Pract. 2017 Oct 30;15:19. doi: 10.1186/s13053-017-0079-4. eCollection 2017.
6
Integrative analysis of genomic and epigenomic regulation of the transcriptome in liver cancer.肝癌中转录组的基因组和表观基因组调控的综合分析。
Nat Commun. 2017 Oct 10;8(1):839. doi: 10.1038/s41467-017-00991-w.
7
Evaluation and Management of Indeterminate Thyroid Nodules: The Revolution of Risk Stratification Beyond Cytological Diagnosis.甲状腺结节性质不明的评估与管理:超越细胞学诊断的风险分层变革
Cancer Control. 2017 Oct-Dec;24(5):1073274817729231. doi: 10.1177/1073274817729231.
8
The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing.全外显子组和转录组测序揭示良性甲状腺结节的遗传全景。
Nat Commun. 2017 Jun 5;8:15533. doi: 10.1038/ncomms15533.
9
Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients.亚洲和西方患者胃腺癌中的体细胞拷贝数改变
PLoS One. 2017 Apr 20;12(4):e0176045. doi: 10.1371/journal.pone.0176045. eCollection 2017.
10
A systematic comparison of copy number alterations in four types of female cancer.四种女性癌症中拷贝数变异的系统比较。
BMC Cancer. 2016 Nov 22;16(1):913. doi: 10.1186/s12885-016-2899-4.